Oncology Imaging Guidelines

Oncology Imaging Guidelines cover advanced and conventional imaging modalities (CT, MRI, PET, nuclear medicine and related procedures) across phases of cancer care — staging, restaging, treatment response, surveillance and screening — for individuals with known or suspected malignancy, cancer predisposition syndromes, and numerous tumor-specific conditions (e.g., primary CNS tumors). Major limitations/requirements include physician review for atypical presentations, a recent clinical evaluation or meaningful contact within 60 days before advanced imaging (unless scheduled surveillance), histologic confirmation and documented stage for medical‑necessity review, adherence to disease‑specific surveillance recommendations, and specified frequency guidance (e.g., ~6–8 weeks during chemotherapy for measurable disease, every 3 months during endocrine therapy); routine imaging is not supported unless explicitly stated.

"68 Gallium DOTATATE (NETSPOT®) for low grade neuroendocrine tumors and medullary thyroid cancer"